DigestRedComo funciona
Red
/
Empresas
Br
No verificado

Bristol Myers Squibb

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

133 Comunicados de prensa

Ver todos los comunicados de prensa
30/04/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Química
Industria
Ciencia
Farmacéutica
Biotecnología
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
24/04/2026
Mercado laboral
Industria
Biotecnología
Sanidad
Salud
Farmacéutica
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
31/03/2026
Análisis de Mercados
Industria
Sanidad
Asociaciones/Profesionales
Cardiología
Gestión empresarial
Biotecnología
Salud
Farmacéutica
Oncología
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
29/03/2026
Eventos
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
28/03/2026
Eventos
Ferias y Congresos
Industria
Psiquiatría
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
23/03/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Cardiología
Biotecnología
Eventos
Industria
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
20/03/2026
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
19/03/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Salud
Ciencia
Farmacéutica
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
09/03/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0
07/03/2026
Industria
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Medicina - Varios
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Fuente
Bristol Myers Squibb
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0